세계의 에어로졸 약물전달 장비 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별 부문 예측(2025-2030년)

Aerosol Drug Delivery Devices Market Size, Share & Trends Analysis Report By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 에어로졸 약물전달 장비 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 에어로졸 약물전달 장비 시장 규모는 2030년까지 621억 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년까지 13.16%의 주목할 만한 CAGR로 확대될 것으로 예측되고 있습니다. 시장 성장을 가속하는 주요 요인으로는 호흡기 질환의 유병률 상승, 의료 의식 증가, 흡입기 기술 진보, 가정 치료 수요 증가 등이 있습니다.

시장 성장의 원동력은 COPD, 천식, 낭포성 섬유증과 같은 호흡기 질환의 유병률 증가, 휴대용 흡입 장비에 대한 관심 증가, 신속하고 효과적인 치료에 대한 요구 등입니다. 기타 요인으로는 정부의 계발 캠페인, 인구의 고령화, 기술의 진보, 장비의 보급률 향상, 도시화, 공해, 연구 개발 증가 등이 있습니다.

시장 개척의 혁신은 생태 친화적인 연료 개발, 환자 어드히어런스 향상을 위한 사용자 인터페이스 디자인 개선, 개인화 진단 및 치료를 위한 AI 활용에 중점을 둡니다. 생분해성 재료의 조사는 장비 구조의 지속 가능한 대안을 제공할 수 있습니다. 시장은 경쟁이 격렬하게 세분화되어 급속한 기술 진보가 끊임없는 변화를 촉진하고 있습니다. 기업은 적극적으로 동향을 도입하고 환자 중심의 친환경 솔루션에 주력하고 성장 기회를 잡고 있습니다.

또한 AptarGroup, Inc., Koninklijke Philips NV, AstraZeneca, Novartis AG와 같은 주요 기업들은 시장 지위를 강화하기 위해 제휴, 공동 연구, 신제품 출시, 인수, 사업 확대 등 전략적 노력을 추진하고 있습니다. 예를 들어, 2024년 1월 Kindeva Drug Delivery은 비강 약물전달을 전문으로 하는 Summit Biosciences의 인수를 발표했습니다.

비강 약물전달은 급성기 또는 응급 상황에서 비침습적으로 약물을 투여할 수 있기 때문에 많은 적응증에서 선호되는 투여 형태가 되고 있습니다. Summit은 비강 전달을 위해 약물을 효과적으로 배합하는 방법과 상업적 규모로 제조하는 능력에 대한 차별화된 이해를 제공합니다. 이번 인수는 약제와 장비의 조합으로 CDMO 시장의 세계 리더가 되는 Kindeva의 야망에 부합할 뿐만 아니라 환자의 결과와 치료 경험의 개선을 지원하기 위해 당사가 고객에게 제공할 수 있는 툴박스를 세계적으로 확대하는 것입니다.

Kindeva CEO Milton Boyer

에어로졸 약물전달 장비 시장 보고서 하이라이트

• 제품 유형별로는 흡입기 시장이 2024년 수익 점유율 89.59%로 시장을 독점했고, 기술적으로 선진적인 제품 개발의 진전과 의료 부문에 있어서의 디지털 솔루션의 채용 확대에 의해 예측 기간 중 CAGR로 가장 빠른 성장이 전망됩니다.
• 응용 분야별로는 COPD 부문이 2024년 최대 시장 점유율을 차지했으며 세계 유병률 상승으로 예측 기간 동안 가장 빠르게 성장할 것으로 예상됩니다.
• 유통 채널별로는 시설 약국 부문이 2024년 최대 시장 점유율을 차지했으며, 대량 약제 유통 요구 증가와 호흡기 질환 환자 인구의 확대가 그 요인이 되고 있습니다.
• 북미는 2024년 39.49% 시장 점유율을 차지했으며 에어로졸 약물전달 장비 산업을 지배했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 에어로졸 약물전달 장비 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 산업 분석
  • 사용자의 시점 분석
  • 주요 최종 사용자
• 기술 전망
• 규제 프레임워크
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 산업의 과제와 기회의 분석
• 에어로졸 약물전달 장비 시장 분석 도구
  • Porter's Five Forces 분석
  • PESTEL 분석
• COVID-19의 영향

제4장 에어로졸 약물전달 장비 시장 : 유형별, 추정 및 동향 분석

• 정의와 범위
• 유형별 시장 점유율 분석, 2024년과 2030년
• 부문 대시보드
• 에어로졸 약물전달 장비 시장 : 유형별, 2018-2030년
  • 분무기
  • 흡입기

제5장 에어로졸 약물전달 장비 시장 : 용도별, 추정 및 동향 분석

• 정의와 범위
• 용도 시장 점유율 분석, 2024년과 2030년
• 부문 대시보드
• 에어로졸 약물전달 장비 시장 : 용도별, 2018-2030년
  • 천식
  • 만성 폐색성 폐질환(COPD)

제6장 에어로졸 약물전달 장비 시장 : 유통 채널별, 추정 및 동향 분석

• 정의와 범위
• 유통 채널 시장 점유율 분석, 2024년과 2030년
• 부문 대시보드
• 에어로졸 약물전달 장비 시장 : 유통 채널별, 2018-2030년
  • 소매 약국
  • 의료기관 약국
  • 온라인 약국

제7장 에어로졸 약물전달 장비 시장 : 지역, 유형, 용도, 유통 채널에 의한 지역별, 추정 및 동향 분석

• 정의와 범위
• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 지역 시장 현황
• SWOT 분석
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 에어로졸 약물전달 장비 시장 점유율, 지역별, 2024년과 2030년, 100만 달러
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 덴마크
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업 분류
• 기업의 시장 점유율 분석
• 기업 히트맵 분석
• 전략 매핑
  • 확대
  • 합병과 인수
  • 파트너십 및 협업
  • 신제품 발매
  • 연구개발
• 기업 프로파일
  • AptarGroup, Inc.
  • Koninklijke Philips NV
  • AstraZeneca
  • Novartis AG
  • Sanofi
  • OMRON Corporation
  • Medline Industries, LP.
  • GF Health Products, Inc.
  • DRIVE MEDICAL GMBH & CO. KG
  • Teva Pharmaceutical Industries Ltd
  • Aerogen(Stamford Devices Limited Group)
  • Sensirion AG
  • PARI Respiratory Equipment, Inc.
  • Catalent, Inc
  • Pfizer Inc.
  • Beurer GmbH

JHS

영문 목차

영문목차

Aerosol Drug Delivery Devices Market Growth & Trends:

The global aerosol drug delivery devices market size is anticipated to reach USD 62.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a notable CAGR of 13.16% from 2025 to 2030. Major factors driving the market growth include the rising prevalence of respiratory diseases, increasing healthcare awareness, advancements in inhaler technology, and the growing demand for home-based treatments.

The market growth is driven by the increasing prevalence of respiratory diseases such as COPD, asthma, and cystic fibrosis, a growing focus on portable inhalation devices, and the need for quick, effective treatments. Other factors include government awareness campaigns, an aging population, technological advancements, higher device adoption, urbanization, pollution, and increased R&D.

Innovation in the market focuses on developing eco-friendly fuels, improving user-interface designs for better patient adherence, and using AI for personalized diagnostics and treatment. Research into biodegradable materials could provide sustainable alternatives for device construction. The market is competitive and fragmented, with rapid technological progress driving constant change. Companies proactively embrace trends, focusing on patient-centered, environmentally friendly solutions to seize growth opportunities.

Moreover, key players in the market, such as AptarGroup, Inc., Koninklijke Philips N.V., AstraZeneca, and Novartis AG, among others, are engaging in strategic initiatives such as partnerships, collaborations, new product launches, acquisitions, and expansions to strengthen their market position. For instance, in January 2024, Kindeva Drug Delivery announced the acquisition of Summit Biosciences, a company specializing in intranasal drug delivery.

"Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting. Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva's ambition to be a global leader in the drug-device combination products CDMO market but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally."

Kindeva CEO Milton Boyer.

Aerosol Drug Delivery Devices Market Report Highlights:

• Based on type, the inhaler segment dominated the market with a revenue share of 89.59% in 2024 and is expected to witness the fastest growth at a CAGR over the forecast period owing to the advancement the development of technologically advanced products, and the growing adoption of digital solutions in the healthcare sector.
• Based on application, the COPD segment held the largest market share in 2024 and is anticipated to be the fastest-growing segment over the forecast period owing to the rising increasing prevalence worldwide.
• Based on the distribution channel, the institutional pharmacies segment held the largest market share in 2024, driven by the increasing need for bulk medication distribution, and the expanding patient population with respiratory conditions.
• North America dominated the aerosol drug delivery devices industry with a market share of 39.49% in 2024, owing to the advanced healthcare infrastructure, increasing geriatric population, and technological advancements.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.1.2. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Aerosol Drug Delivery Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Industry Analysis
  • 3.2.1. User Perspective Analysis
  • 3.2.2. Key End Users
• 3.3. Technology Outlook
• 3.4. Regulatory Framework
• 3.5. Market Dynamics
  • 3.5.1. Market Drivers Analysis
    • 3.5.1.1. Rising prevalence of respiratory diseases
    • 3.5.1.2. Technological advancements
    • 3.5.1.3. Rising geriatric population
    • 3.5.1.4. Increasing awareness of self-medication and home healthcare
  • 3.5.2. Market Restraints Analysis
    • 3.5.2.1. High cost of devices
  • 3.5.3. Industry Challenges and Opportunity Analysis
• 3.6. Aerosol Drug Delivery Devices Market Analysis Tools
  • 3.6.1. Porter's Analysis
    • 3.6.1.1. Bargaining power of the suppliers
    • 3.6.1.2. Bargaining power of the buyers
    • 3.6.1.3. Threats of substitution
    • 3.6.1.4. Threats from new entrants
    • 3.6.1.5. Competitive rivalry
  • 3.6.2. PESTEL Analysis
    • 3.6.2.1. Political landscape
    • 3.6.2.2. Economic and Social landscape
    • 3.6.2.3. Technological landscape
    • 3.6.2.4. Environmental landscape
    • 3.6.2.5. Legal Landscape
• 3.7. Impact of COVID-19

Chapter 4. Aerosol Drug Delivery Devices Market: Type Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Type Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Aerosol Drug Delivery Devices Market: By Type, 2018 to 2030
  • 4.4.1. Nebulizers
    • 4.4.1.1. Nebulizers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.2. Jet
      • 4.4.1.2.1. Jet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.3. Mesh
      • 4.4.1.3.1. Mesh Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.4. Active
      • 4.4.1.4.1. Active Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.5. Passive
      • 4.4.1.5.1. Passive Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.6. Ultrasonic
      • 4.4.1.6.1. Ultrasonic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Inhaler
    • 4.4.2.1. Inhaler Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.2. Pressurized Metered-Dose Inhaler (PMDI)
      • 4.4.2.2.1. Pressurized Metered-Dose Inhaler (PMDI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.3. Dry-Powder Inhaler (DPI)
      • 4.4.2.3.1. Dry-Powder Inhaler (DPI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Aerosol Drug Delivery Devices Market: Application Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Aerosol Drug Delivery Devices Market: By Application, 2018 to 2030
  • 5.4.1. Asthma
    • 5.4.1.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 5.4.2.1. Chronic Obstructive Pulmonary Disease (COPD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Aerosol Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. Distribution Channel Market Share Analysis, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. Aerosol Drug Delivery Devices Market: By Distribution Channel, 2018 to 2030
  • 6.4.1. Retail Pharmacies
    • 6.4.1.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Institutional Pharmacies
    • 6.4.2.1. Institutional Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Online Pharmacies
    • 6.4.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Aerosol Drug Delivery Devices Market: Regional Estimates & Trend Analysis by Region, Type, Application, Distribution Channel

• 7.1. Definition and Scope
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Regional Market Dashboard
• 7.4. Regional Market Snapshot
• 7.5. SWOT Analysis
  • 7.5.1. North America
  • 7.5.2. Europe
  • 7.5.3. Asia Pacific
  • 7.5.4. Latin America
  • 7.5.5. Middle East & Africa
• 7.6. Aerosol Drug Delivery Devices Market Share, By Region, 2024 & 2030, USD Million
• 7.7. North America
  • 7.7.1. North America Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. U.S.
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. U.S. Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Canada
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Canada Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. Mexico
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.7.4.3. Competitive Insights
    • 7.7.4.4. Canada Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Europe
  • 7.8.1. Europe Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. UK
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. UK Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Germany
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Germany Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. France
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. France Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Italy
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Italy Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.6. Spain
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.6.3. Competitive Insights
    • 7.8.6.4. Spain Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.7. Sweden
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.7.3. Competitive Insights
    • 7.8.7.4. Sweden Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.8. Denmark
    • 7.8.8.1. Key Country Dynamics
    • 7.8.8.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.8.3. Competitive Insights
    • 7.8.8.4. Sweden Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.9. Norway
    • 7.8.9.1. Key Country Dynamics
    • 7.8.9.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.9.3. Competitive Insights
    • 7.8.9.4. Sweden Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Asia Pacific
  • 7.9.1. Asia Pacific Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. China
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.2.3. Competitive Insights
    • 7.9.2.4. China Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Japan
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.3.3. Competitive Insights
    • 7.9.3.4. Japan Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. India
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.4.3. Competitive Insights
    • 7.9.4.4. India Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. South Korea
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.5.3. Competitive Insights
    • 7.9.5.4. South Korea Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.6. Australia
    • 7.9.6.1. Key Country Dynamics
    • 7.9.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.6.3. Competitive Insights
    • 7.9.6.4. Australia Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.7. Thailand
    • 7.9.7.1. Key Country Dynamics
    • 7.9.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.7.3. Competitive Insights
    • 7.9.7.4. Thailand Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Latin America
  • 7.10.1. Latin America Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.2. Brazil
    • 7.10.2.1. Key Country Dynamics
    • 7.10.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.10.2.3. Competitive Insights
    • 7.10.2.4. Brazil Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.3. Argentina
    • 7.10.3.1. Key Country Dynamics
    • 7.10.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.10.3.3. Competitive Insights
    • 7.10.3.4. Argentina Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.11. Middle East and Africa
  • 7.11.1. Middle East and Africa Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.2. South Africa
    • 7.11.2.1. Key Country Dynamics
    • 7.11.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.2.3. Competitive Insights
    • 7.11.2.4. South Africa Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.3. Saudi Arabia
    • 7.11.3.1. Key Country Dynamics
    • 7.11.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.3.3. Competitive Insights
    • 7.11.3.4. Saudi Arabia Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.4. UAE
    • 7.11.4.1. Key Country Dynamics
    • 7.11.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.4.3. Competitive Insights
    • 7.11.4.4. UAE Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.5. Kuwait
    • 7.11.5.1. Key Country Dynamics
    • 7.11.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.5.3. Competitive Insights
    • 7.11.5.4. UAE Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
• 8.6. Company Profiles
  • 8.6.1. AptarGroup, Inc.
    • 8.6.1.1. Participant's Overview
    • 8.6.1.2. Financial Performance
    • 8.6.1.3. Product Benchmarking
    • 8.6.1.4. Recent Developments
  • 8.6.2. Koninklijke Philips N.V.
    • 8.6.2.1. Participant's Overview
    • 8.6.2.2. Financial Performance
    • 8.6.2.3. Product Benchmarking
    • 8.6.2.4. Recent Developments
  • 8.6.3. AstraZeneca
    • 8.6.3.1. Participant's Overview
    • 8.6.3.2. Financial Performance
    • 8.6.3.3. Product Benchmarking
    • 8.6.3.4. Recent Developments
  • 8.6.4. Novartis AG
    • 8.6.4.1. Participant's Overview
    • 8.6.4.2. Financial Performance
    • 8.6.4.3. Product Benchmarking
    • 8.6.4.4. Recent Developments
  • 8.6.5. Sanofi
    • 8.6.5.1. Participant's Overview
    • 8.6.5.2. Financial Performance
    • 8.6.5.3. Product Benchmarking
    • 8.6.5.4. Recent Developments
  • 8.6.6. OMRON Corporation
    • 8.6.6.1. Participant's Overview
    • 8.6.6.2. Financial Performance
    • 8.6.6.3. Product Benchmarking
    • 8.6.6.4. Recent Developments
  • 8.6.7. Medline Industries, LP.
    • 8.6.7.1. Participant's Overview
    • 8.6.7.2. Financial Performance
    • 8.6.7.3. Product Benchmarking
    • 8.6.7.4. Recent Developments
  • 8.6.8. GF Health Products, Inc.
    • 8.6.8.1. Participant's Overview
    • 8.6.8.2. Financial Performance
    • 8.6.8.3. Product Benchmarking
    • 8.6.8.4. Recent Developments
  • 8.6.9. DRIVE MEDICAL GMBH & CO. KG
    • 8.6.9.1. Participant's Overview
    • 8.6.9.2. Financial Performance
    • 8.6.9.3. Product Benchmarking
    • 8.6.9.4. Recent Developments
  • 8.6.10. Teva Pharmaceutical Industries Ltd
    • 8.6.10.1. Participant's Overview
    • 8.6.10.2. Financial Performance
    • 8.6.10.3. Product Benchmarking
    • 8.6.10.4. Recent Developments
  • 8.6.11. Aerogen (Stamford Devices Limited Group)
    • 8.6.11.1. Participant's Overview
    • 8.6.11.2. Financial Performance
    • 8.6.11.3. Product Benchmarking
    • 8.6.11.4. Recent Developments
  • 8.6.12. Sensirion AG
    • 8.6.12.1. Participant's Overview
    • 8.6.12.2. Financial Performance
    • 8.6.12.3. Product Benchmarking
    • 8.6.12.4. Recent Developments
  • 8.6.13. PARI Respiratory Equipment, Inc.
    • 8.6.13.1. Participant's Overview
    • 8.6.13.2. Financial Performance
    • 8.6.13.3. Product Benchmarking
    • 8.6.13.4. Recent Developments
  • 8.6.14. Catalent, Inc
    • 8.6.14.1. Participant's Overview
    • 8.6.14.2. Financial Performance
    • 8.6.14.3. Product Benchmarking
    • 8.6.14.4. Recent Developments
  • 8.6.15. Pfizer Inc.
    • 8.6.15.1. Participant's Overview
    • 8.6.15.2. Financial Performance
    • 8.6.15.3. Product Benchmarking
    • 8.6.15.4. Recent Developments
  • 8.6.16. Beurer GmbH
    • 8.6.16.1. Participant's Overview
    • 8.6.16.2. Financial Performance
    • 8.6.16.3. Product Benchmarking
    • 8.6.16.4. Recent Developments

관련자료